Historical review from 2026-09-14. Current price and availability are unconfirmed; check the original marketplace.
Insect Bite ID generates $2.8K/mo with an exceptional 99.9% profit margin and 2.25x annual profit multiple — both attractive metrics. However, the extremely high margin (nearly 100%) and lack of disclosed business age or customer/retention data warrant careful verification before acquisition. The verified-financials status on TrustMRR is a meaningful confidence factor, but a buyer should independently confirm the margin calculation, customer base size, churn, and whether the current pricing or cost structure is sustainable at scale.
The core software — image upload, AI-based insect-bite classification using a hosted vision model, care-advice templates, and simple bite-tracking storage — is reproducible in 6 weeks with an AI coding subscription ($30–60/mo), a vision API (Claude, GPT-4 Vision, or open-source model), and managed database hosting. The real acquisition asset is the paying-customer base and their retention behavior, which is not disclosed here. Without evidence of customer count, acquisition channels, retention rate, or competitive defensibility, the software cost advantage outweighs the unverified traction. A buyer should request customer metrics; if churn is low and customer base is >20 active paid accounts, the case for buying strengthens. At current price and missing traction details, building carries less risk.
Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.
Snap a photo to identify insect bites in seconds with AI. Get confidence scores, bite care advice, and track bites over time for extra peace of mind.
Opens the original listing on TrustMRR
Get new listings with asking prices, monthly profit, deal scores, and key risks.
The best reviewed deals, concise and evidence-first. Unsubscribe anytime.
Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.